As Profits Rise, Ocular Science Promotes From Within

Eric Garner Named VP of Marketing for SoCal Biotech

MANHATTAN BEACH, Calif. (Jan. 15, 2020) – Ocular Science®, which produces and markets ophthalmic medications for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has promoted Eric Garner to Vice President of Marketing.  Garner, hired in March 2019 as director of marketing, has led corporate branding efforts, developed digital ad campaigns and will soon be rolling out a national public relations campaign.  His recent work includes developing and implementing the communications strategies for the introduction for two Ocular Science affiliates: OSRX®, a 503A compounding pharmacy; and Regenerative Science.

“Eric’s youth belies his knowledge of all phases of marketing. He instantly jumped into this job and began reshaping our communications from the ground up,” says Ocular Science founder and CEO Anthony Sampietro.  “He has revamped and formalized all of our branding, built three websites, developed our corporate digital footprint, worked seamlessly within our industry and has become a recognized ophthalmology marketing expert in a very short amount of time. 

“Incidentally, our compound annual growth rate was more than 90 percent in 2019 and Eric’s marketing contributions were a crucial component of that expansion.”

Prior to joining Ocular Science, Garner managed communications for Beach Cities Health District, one of the nation’s largest preventive health agencies, and spent time in the private sector providing public relations and marketing services to automotive clients including Yokohama Tires, TrueCar, Volvo and the Pebble Beach Concours d’Elegance. 

For more information on Ocular Science and its affiliates, visit

Media Contact: Eric Garner, Ocular Science – (541) 413-2880;

OSRX operates in compliance with Section 503A regarding compounded drugs as defined in the FD&C Act.

*Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. 503A compounding pharmacies are not required to comply with cGMP requirements but can be inspected by FDA. References available upon request.

Click here to view potential contraindications.